Search the Newsreel

Exagen Inc. (NASDAQ:XGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Qiagen N.V. $QGEN Shares Sold by Edgestream Partners L.P.

(RARE) Risk Channels and Responsive Allocation

This article analyzes Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) using AI models, indicating weak sentiment across all horizons which supports a short bias. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights an exceptional …

Ultragenyx Pharmaceutical, Inc. Revenue Breakdown – BX:UP0

Ultragenyx Pharmaceutical, Inc. (UP0) generated 533.53 million CHF in revenue last year, primarily from its Novel Products segment. The company's largest regional contribution came from North America, accounting for 298.87 million CHF. This financial overview highlights the company's key revenue drivers and geographical performance.

Arrowstreet Capital Limited Partnership Buys 761,685 Shares of Niagen Bioscience, Inc. $NAGE

Arrowstreet Capital Limited Partnership significantly increased its stake in Niagen Bioscience, Inc. (NASDAQ:NAGE) by purchasing 761,685 additional shares in the first quarter, bringing its total holdings to 2,378,437 shares valued at $10.489 million. Other institutional investors like JPMorgan Chase & Co., SteelPeak Wealth LLC, …

Volkswagen (XTRA:VOW3) Weighs JSW Deal That Could Recast Its India Business

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Volkswagen (XTRA:VOW3) is in advanced talks with JSW Group about a potential partnership or sale of its India operations. The discussions focus on …

Form 4 VistaGen Therapeutics Inc For: 31 July By Investing.com

This article reports on a Form 4 filing for VistaGen Therapeutics Inc. as of July 31. Form 4s disclose transactions made by company insiders and are important for investors to track. The article is very brief, serving primarily as an announcement of the filing …

Agenus (NASDAQ:AGEN) Stock Rating Upgraded by Wall Street Zen

Qiagen (QGEN) Stock Could Be A Cash Flow Bargain Yet Fair On Earnings

Press Release: Vistagen Appoints Douglas J. Williamson to Its Board of Directors

Vistagen Therapeutics, Inc. has announced the appointment of Douglas J. Williamson, M.D. to its Board of Directors. Dr. Williamson brings extensive experience in psychiatric drug development and will also serve on the Nominating & Corporate Governance Committee. This appointment expands Vistagen's Board to eight …

Qiagen NV (QGEN.BRN) Q4 2024 Earnings Report - Results, Call & Slides

Qiagen NV (QGEN.BRN) reported its Q4 2024 earnings, missing the consensus EPS estimate by -CHF0.01 with an actual EPS of CHF0.52. However, the company beat revenue expectations, reporting CHF424.78M against an expected CHF424.66M, marking a 2.36% year-over-year revenue growth. The earnings call and slide …

Vanguard Portfolio Management (RARE) discloses 6.85M-share Ultragenyx stake on 13G/A

Vanguard Portfolio Management LLC, along with affiliates, has reported a beneficial ownership of 6,853,427 shares of Ultragenyx Pharmaceutical Inc. common stock as of June 30, 2026. This stake represents 6.95% of the outstanding class, with Vanguard holding sole voting power over 63,292 shares and …

AGEN|Agenus Inc|Price:7.500|Chg%:-0.410

TradingKey provides a comprehensive stock analysis for Agenus Inc (AGEN), highlighting its stable fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. The analysis notes high institutional ownership and recent "Buy" ratings from analysts with a target price …

Vistagen Therapeutics (NASDAQ: VTGN) sets 2026 virtual meeting, director slate and pay vote

Vistagen Therapeutics (NASDAQ: VTGN) has announced its 2026 annual virtual meeting for September 10, 2026. Stockholders will vote on the election of four directors, a non-binding advisory vote on Named Executive Officer compensation, and the ratification of KPMG LLP as the independent auditor. The …

Vistagen Therapeutics Inc (VTGN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Vistagen Therapeutics Inc (VTGN), ranking it 315 out of 385 in the Biotechnology & Medical Research industry with a score of 1.25. It highlights the company's beta value of 0.31, indicating lower volatility compared to the S&P …

Ultragenyx Pharmaceutical Inc (RARE) Institutional Confidence

Ultragenyx Pharmaceutical Inc (RARE) has an institutional shareholding score of 10.00, ranking 1st in the Pharmaceuticals industry. The institutional shareholding proportion increased by 3.72% quarter-over-quarter, reaching 107.82%. Frank Sands is the largest institutional shareholder, holding 3.28% of outstanding shares.

Vanguard Capital Management (RARE) discloses 5.13% Ultragenyx ownership on Schedule 13G

Vanguard Capital Management has reported a 5.13% beneficial ownership stake in Ultragenyx Pharmaceutical Inc., according to a Schedule 13G filing. This amounts to 5,058,419 shares, with Vanguard holding sole voting power over 761,928 shares and sole dispositive power over all 5,058,419 shares. The filing …

Vistagen Therapeutics (Nasdaq: VTGN) names Douglas J. Williamson to board

Vistagen Therapeutics, Inc. (Nasdaq: VTGN) has appointed Douglas J. Williamson, M.D. to its Board of Directors, effective July 29, 2026. Dr. Williamson, who has nearly three decades of experience in neuroscience drug development, received stock options and will be compensated under the company's Director …

VistaGen files Form 3 as director Douglas J. Williamson reports no beneficial ownership

VistaGen Therapeutics director Douglas J. Williamson has filed an initial Form 3, indicating no beneficial ownership. This filing was made on July 31, 2026, and the information was originally published via EDGAR by VistaGen Therapeutics Inc. The news brief is an AI-generated content for …

Vistagen adds board director with nearly three decades in neuroscience drug development

Vistagen (Nasdaq: VTGN) has appointed Douglas J. Williamson, MD, to its Board of Directors, leveraging his nearly three decades of experience in neuroscience drug development, clinical research, and regulatory strategy. Dr. Williamson's background includes leadership roles at several biopharmaceutical companies and contributions to the …

QGEN|Qiagen NV|Price:41.435|Chg%:-0.375

This article provides a detailed analysis of Qiagen NV (QGEN) stock, highlighting its current market trends, real-time quotes, and related analysis. It covers key financial figures, insights into its growth potential and valuation, and analyst ratings, which currently lean towards "Buy." The company's strengths …

Amundi Has $190.50 Million Stake in Qiagen N.V. $QGEN

Amundi increased its stake in Qiagen N.V. by 12.4% in the first quarter, now holding 4.76 million shares valued at $190.5 million, representing 2.31% of the company.

VTGN Q2 2026 Earnings: Wider-Than-Expected Loss Signals Rising Clinical Costs - Earnings Decline Risk

Exagen Inc (XGN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Exagen Inc (XGN), highlighting its current valuation score of 7.83 and its ranking within the Healthcare Providers & Services industry. It details the company's P/E ratio, noting its current value relative to recent highs and lows. The …

ImageneBio, Inc. Revenue Breakdown – NASDAQ:IMA

ImageneBio Inc. (IMA) Q1 2026 Earnings: EPS Miss Highlights Pre‑Revenue Challenges as Stock Rises

BlackRock (RARE holder) discloses 8.3% Ultragenyx stake in amended 13G

BlackRock, Inc. has filed an amended Schedule 13G, disclosing an 8.3% beneficial ownership stake in Ultragenyx Pharmaceutical Inc., totaling 8,141,384 shares. BlackRock primarily holds sole voting and dispositive power over these shares, with no single underlying client exceeding a 5% interest. This filing indicates …

PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG

This article announces that QIAGEN N.V. has published a voting rights notification in accordance with § 40 Abs. 1 WpHG, as informed by the AFM on July 29, 2026. The notification details various share and voting rights distributions related to Goldman Sachs Group Inc., …

Vistagen Therapeutics Q2 2026 Earnings: EPS Miss Alters Sentiment as Stock Rises - Annual Earnings Summary

Agenus posts corporate presentation spotlighting botensilimab-balstilimab neoadjuvant strategy in MSS colon cancer

Agenus has detailed its registrational Phase 3 "ROBBIN" trial for botensilimab with balstilimab in neoadjuvant MSS colon cancer, targeting 850 patients with event-free survival as the primary endpoint. Initial investigator studies showed promising pathologic complete response rates. The trial is expected to begin in …

Agenus (AGEN) Earnings Expected to Grow: Should You Buy?

The market expects Agenus (AGEN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence …

B. Riley Adjusts Agenus Price Target to $14 From $8, Maintains Buy Rating

B. Riley has adjusted its price target for Agenus Inc. to $14 from $8, while simultaneously maintaining a Buy rating on the stock. This update reflects an increased positive outlook from the analyst firm regarding the biotechnology company. The article mentions that Agenus is …

AGEN Earnings Overview 2026-07-30 - Annual Financial Report

Vistagen Therapeutics Q2 2026 Earnings: EPS Miss Alters Sentiment as Stock Rises - Earnings Per Share

Qiagen (QGEN) Edges Lower as Biotech Sector Faces Headwinds - Growth ETF

Vistagen Therapeutics Q2 2026 Earnings: EPS Miss Alters Sentiment as Stock Rises - Earnings Quality Score